Abstract: A light emitting apparatus according to the present disclosure includes a first layer made of a semiconductor monocrystal, a second layer provided at the first layer and having a crystal orientation not continuous with the crystal orientation of the first layer, and a columnar crystal structure including a light emitting layer and extending from the second layer.

Abstract: A liquid for cryopreserving a cell and a liquid for administration of a mammalian cell capable of cryopreserving a mammalian cell and effectively suppressing cell death after thawing, and a method for cryopreserving a mammalian cell using the cell cryopreservation liquid. The liquid is an isotonic solution that includes 2.0 to 6.0% (w/v) of trehalose or a derivative thereof, or a salt of the trehalose or the derivative, 4.0 to 7.0% (w/v) of dextran or a derivative thereof, or a salt of the dextran or the derivative, and DMSO or glycerin.

Abstract: The present invention addresses the problem of providing, for instance, a mammalian cell preservation solution that can effectively suppress a decrease in cell viability occurring when mammalian cells are preserved in liquid or a decrease in self-renewal potential occurring when mammalian stem cells are preserved in liquid, and that is less likely to cause a harmful effect on the life of a mammal at the time of in vivo administration of mammalian cells to the mammal. This solution involves preserving a mammalian cell by using a mammalian cell preservation solution comprising trehalose or a derivative thereof, or a salt thereof and a hydrogen carbonate, such as sodium bicarbonate, as a pH modifier, and having a pH of from 6.5 to 8.5.

Abstract: An object of the present invention is to provide a novel preservation solution for preserving mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin is added to an isotonic solution to prepare a preservation solution. The preservation solution is mixed with platelets and preserved under shaking. Decrease in the functions and viability of the platelets can thereby be suppressed for at least 10 days. Alternatively, the aforementioned preservation solution is mixed with mesenchymal stem cells, megakaryocytes, or T cells and preserved in a non-frozen state. Decrease in the functions and viability of these cells can thereby be suppressed for at least several days to several tens of days.

Abstract: The present invention provides a method of producing a sheet-like pancreatic islet, comprising culturing an isolated pancreatic islet in a culture vessel, wherein a polypeptide comprising an EC1 domain of E-cadherin and having a binding ability to said E-cadherin is fixed on or applied to a surface of a solid phase, while being adhered to the solid phase surface for a period sufficient for the pancreatic islet to take a sheet-like form.

Abstract: An object of the present invention is to provide stem cells having excellent proliferation ability and differentiation ability. The present invention relates to stem cells isolated from a neonatal pig, and a preparation method therefor.

Abstract: A liquid for cryopreserving a cell and a liquid for administration of a mammalian cell capable of cryopreserving a mammalian cell and effectively suppressing cell death after thawing, and a method for cryopreserving a mammalian cell using the cell cryopreservation liquid. The liquid is an isotonic solution that includes 2.0 to 6.0% (w/v) of trehalose or a derivative thereof, or a salt of the trehalose or the derivative, 4.0 to 7.0% (w/v) of dextran or a derivative thereof, or a salt of the dextran or the derivative, and DMSO or glycerin.

Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

Abstract: The present invention provides: a superficial cerebral vascular bleeding inhibitor comprising an aqueous solution containing 120 to 160 mEq/L of sodium ion, 1 to 5 mEq/L of calcium ion, and 75 to 165 mEq/L of chloride ion; the superficial cerebral vascular bleeding inhibitor further comprising 1 to 5 mEq/L of potassium ion; and a packaged container containing the superficial cerebral vascular bleeding inhibitor (with or without potassium ion). The superficial cerebral vascular bleeding inhibitor of the present invention can effectively prevent or inhibit bleeding from superficial cerebral blood vessels in the field of neurosurgery such as intracranial surgery and the like, thereby capable of securing a clear operating field during intracranial surgery and inhibiting the occurrence of post-surgery damage.

Abstract: The present invention provides a method of producing a sheet-like pancreatic islet, comprising culturing an isolated pancreatic islet in a culture vessel, wherein a polypeptide comprising an EC1 domain of E-cadherin and having a binding ability to said E-cadherin is fixed on or applied to a surface of a solid phase, while being adhered to the solid phase surface for a period sufficient for the pancreatic islet to take a sheet-like form.

Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

Abstract: The present invention provides: a superficial cerebral vascular bleeding inhibitor comprising an aqueous solution containing 120 to 160 mEq/L of sodium ion, 1 to 5 mEq/L of calcium ion, and 75 to 165 mEq/L of chloride ion; the superficial cerebral vascular bleeding inhibitor further comprising 1 to 5 mEq/L of potassium ion; and a packaged container containing the superficial cerebral vascular bleeding inhibitor (with or without potassium ion). The superficial cerebral vascular bleeding inhibitor of the present invention can effectively prevent or inhibit bleeding from superficial cerebral blood vessels in the field of neurosurgery such as intracranial surgery and the like, thereby capable of securing a clear operating field during intracranial surgery and inhibiting the occurrence of post-surgery damage.